VYNE News and Press, VYNE Therapeutics Inc Com From 08/12/21

VYNE Therapeutics Inc. (VYNE) Q2 2021 Earnings Conference Call August 12, 2021 08:30 AM ET Company Participants Chase Oswald - Investor Relations, LifeSci Advisors Dave Domzalski - President & Chief Executive Officer Tyler Zeronda - Chief Financial Officer Iain Stuart - Chief Scientific O...

Gainers: NanoVibronix (NASDAQ:NAOV) +27%, Apyx Medical (NASDAQ:APYX) +20%, Xenetic Biosciences (NASDAQ:XBIO) +19%, Doximity (NYSE:DOCS) +15%, OncoCyte (NASDAQ:OCX) +14%. Losers: MedAvail (NASDAQ:MDVL) -51%, LifeStance Health (NASDAQ:LFST) -49%...

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise Phase 2a results for FMX114 expected by year end and VYN201 and VYN...

VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic in ...

VYNE Therapeutics (NASDAQ:VYNE) perks up 4% premarket after announcing that its products AMZEEQ (minocycline) topical foam, 4%, and ZILXI (minocycline) topical foam, 1.5%, have been approved for commercial sale in a pilot program in Hainan Boao Lecheng, China. The drug will be sold ...

Ever-Glory EVK +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Moderna sign Option and License Agr...

BRIDGEWATER, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its products AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%, have been approve...

BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens....

VYNE Therapeutics (VYNE) announces the initiation of an investigator initiated trial evaluating the safety and efficacy of AMZEEQ (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne.The trial is a randomized, multicenter, ev...

BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety and efficac...